Dr. Michael C. Haffner, M.D.
Pathology (Anatomic Pathology Physician)
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 20
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 159
Licensed in Washington since 2019, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Anatomic Pathology Physician primary
WA license MD60960832 (first issued 2019; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Washington Medical Ctr Seattle, WA
- Harborview Medical Center Seattle, WA
Medical groups
- The Association of University Physicians (3,535 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 159
- Services billed
- 277
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Special stained specimen slides to examine tissue, each additional procedure | 61 | 22 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 59 | 59 |
| Pathology examination of tissue using a microscope, intermediate complexity | 56 | 32 |
| Pathology examination of tissue using a microscope, moderately high complexity | 44 | 31 |
| Special stained specimen slides to examine tissue, initial procedure | 30 | 27 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $730 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $730 |
|---|
| Consulting Fee | $730 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Mar 8, 2025 | Consulting Fee | $730 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $118,826 in research payments for these studies, mostly to the institutions running them.
- Molecular and genonmic correlates of androgen receptor ("ar") dependency in advanced metastatic prostate cancer patients
Genentech, Inc. - Study name not reported
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.